Lecture Series on Neuropsychiatric Disorders
Online Zoom Meeting Link: https://zoom.com.cn/j/84603647228?pwd=WG1mcDlQSTBraG85MEsyblFVditvZz09
Meeting ID: 846 0364 7228
10:00-11:30, Friday, July 17th, 2020
Piu Chan, MD, PhD
Xuanwu Hospital of Capital Medical University
Dr. Dai Zhang
Parkinson’s Disease: Critical Issues on Clinical and Translational Research
Parkinson’s disease (PD) is the second most common neurodegenerative disorders and has become a significant burden to the fast aging society due to its higher prevalence, higher rate of disability and long disease duration. It’s known that PD has a multifactorial etiology and is pathologically characterized by the selective loss of dopaminergic neurons in the substantia nigra due to alpha-synuclein aggregation which also exists in the nerve terminals of multiple body systems. Motor and non-motor symptoms are the cardinal signs presented cross the pre-clinical and clinical stages of the disease. There is no cure so far for PD but many drugs can improve the motor symptoms and quality of life through dopamine replacement therapy. By now, there is no subjective marker for early diagnosis and monitoring disease progression. Current focuses of research mainly include: (1) mechanisms underlying neurodegeneration, (2) biomarkers for early diagnosis and disease progression, (3) neuroplasticity involved in levodopa induced motor fluctuations and deep brain stimulation, and (4) neuron repair and regeneration.
Professor Piu Chan graduated from Hunan Medical College in Changsha in 1983 and became a neurologist after the fellowship training. He later acquired his Doctor of Philosophy in neurosciences from Sun Yan-Sen University of Medical Sciences in Guangzhou in 1990 followed by postdoctoral training at the Parkinson's Institute in Sunnyvale, California of USA, where he spent more than 10 years as senior scientist before returning to Beijing in 1998. After return, Dr. Chan had established the Center for Neurodegenerative Diseases and Clinic for Parkinson’s disease which later became part of the Key Laboratory of Ministry of Education on Neurodegenerative Disorders, Research and Clinical Center for Parkinson’s disease of Capital Medical University, Parkinson Disease Center of Beijing Institute for Brain Disorders and Key Laboratory on Parkinson’s Disease of Beijing. Now this center serves more than 40,000 visits of patients with Parkinson’s disease annually.
Dr. Chan is well known for his translational research on neurodegenerative disorders. Collaborating with Dr. Carlie Tanner on several unique cohorts, they were the first reporting that environmental exposures are the major risk factors for Parkinson’s disease in 1980’s. He has worked with Dr. J William Langston on developing non-human primate models of Parkinson’s disease and dyskinesia. By using microwave technology, he first demonstrated that MPTP causes selective energy impairment in the striatum leading to neurodegeneration. He has been studying familial and susceptibility genes and a variety of biomarkers for Parkinson's diseases in a few unique cohorts in China aimed for prediction and prevention of neurodegenerative diseases. He has found the China Parkinson Alliance with more than 550 medical centers and 2000+ neurologists, and the first Virtual Hospital on Parkinson’s disease. He has participated in drafting “MDS Diagnostic Criteria for Parkinson’s Disease” and “MDS Research Diagnostic Criteria for Prodromal Parkinson’s disease”. Dr. Chan’s team has participated in the International LRRK2 Consortium and Apple’s mPower projects. He has been awarded by the China Ministry of Sciences and Technology to establish the National Consortium and Big Data Platform for Parkinson and Alzheimer’s diseases.
Dr. Chan also found the Faculty of Geriatrics of Capital Medical University, the first in China in 2004, and established the Beijing Longitudinal Study on Aging II cohort for investigating Frailty and Neurodegenerative disorders. He has initiated projects investigating the role of polyphenols (funded by M. J. Fox foundation) and Traditional Chinese Medicine in two multi-center trials. He has been the Principal investigator for about 20 Phase I-IV clinical trials. He is an ad hoc consultant for the State Food and Drug Administration of China.
Dr. Chan is currently a Professor and the department head of Neurobiology and Geriatrics and vice director of Neurology in the Xuanwu Hospital of Capital Medical University. He also serves as the Director of National Clinical Research Center for Geriatric Disorders. He has published more than 300 SCI peer-reviewed papers with a citation of 14,770 and h-index 57 in Google Scholar, and about 250 peer-reviewed Chinese papers with a citation of ~10,000 and served as editorial members of more than 15 international journals.